These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29247125)

  • 1. Incidence of hip and knee replacement in patients with rheumatoid arthritis following the introduction of biological DMARDs: an interrupted time-series analysis using nationwide Danish healthcare registers.
    Cordtz RL; Hawley S; Prieto-Alhambra D; Højgaard P; Zobbe K; Overgaard S; Odgaard A; Kristensen LE; Dreyer L
    Ann Rheum Dis; 2018 May; 77(5):684-689. PubMed ID: 29247125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between NICE guidance on biologic therapies with rates of hip and knee replacement among rheumatoid arthritis patients in England and Wales: An interrupted time-series analysis.
    Hawley S; Cordtz R; Dreyer L; Edwards CJ; Arden NK; Delmestri A; Silman A; Cooper C; Judge A; Prieto-Alhambra D
    Semin Arthritis Rheum; 2018 Apr; 47(5):605-610. PubMed ID: 29055489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in Upper Limb Joint Surgery Among Rheumatoid Arthritis Patients: An Interrupted Time-Series Analysis Using Danish Health Care Registers.
    Cordtz R; Hawley S; Prieto-Alhambra D; Højgaard P; Zobbe K; Kristensen LE; Overgaard S; Odgaard A; Soussi BG; Dreyer L
    Arthritis Care Res (Hoboken); 2020 Feb; 72(2):274-282. PubMed ID: 30680930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of revision, prosthetic joint infection and mortality following total hip or total knee arthroplasty in patients with rheumatoid arthritis: a nationwide cohort study using Danish healthcare registers.
    Cordtz RL; Zobbe K; Højgaard P; Kristensen LE; Overgaard S; Odgaard A; Lindegaard H; Dreyer L
    Ann Rheum Dis; 2018 Feb; 77(2):281-288. PubMed ID: 29097373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of biologics on reducing the risks of total knee replacement and total hip replacement in rheumatoid arthritis.
    Chang YS; Chen JH; Lin TM; Hsu HC; Chen WS; Lin SH; Kuo PI; Lin YC; Chang CC
    Rheumatology (Oxford); 2022 May; 61(5):1849-1856. PubMed ID: 34534283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Has the incidence of total joint arthroplasty in rheumatoid arthritis decreased in the era of biologics use? A population-based cohort study.
    Zhou VY; Lacaille D; Lu N; Kopec JA; Garbuz DS; Qian Y; Aviña-Zubieta JA; Esdaile JM; Xie H
    Rheumatology (Oxford); 2022 May; 61(5):1819-1830. PubMed ID: 34373899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Descriptive epidemiology of hip and knee replacement in rheumatoid arthritis: An analysis of UK electronic medical records.
    Hawley S; Edwards CJ; Arden NK; Delmestri A; Cooper C; Judge A; Prieto-Alhambra D
    Semin Arthritis Rheum; 2020 Apr; 50(2):237-244. PubMed ID: 31492436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of revision for infection in primary total hip and knee arthroplasty in patients with rheumatoid arthritis compared with osteoarthritis: a prospective, population-based study on 108,786 hip and knee joint arthroplasties from the Norwegian Arthroplasty Register.
    Schrama JC; Espehaug B; Hallan G; Engesaeter LB; Furnes O; Havelin LI; Fevang BT
    Arthritis Care Res (Hoboken); 2010 Apr; 62(4):473-9. PubMed ID: 20391501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype.
    Hellgren K; Di Giuseppe D; Smedby KE; Sundström C; Askling J; Baecklund E;
    Rheumatology (Oxford); 2021 Feb; 60(2):809-819. PubMed ID: 32810256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of TNF inhibitor therapy on joint replacement rates in rheumatoid arthritis: a matched cohort analysis of BSRBR-RA UK registry data.
    Hawley S; Ali MS; Cordtz R; Dreyer L; Edwards CJ; Arden NK; Cooper C; Judge A; Hyrich K; Prieto-Alhambra D
    Rheumatology (Oxford); 2019 Jul; 58(7):1168-1175. PubMed ID: 30649521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of total hip and knee joint replacement in patients with rheumatoid arthritis and osteoarthritis: a nationwide, population-based study.
    Liao CY; Chan HT; Chao E; Yang CM; Lu TC
    Singapore Med J; 2015 Jan; 56(1):58-64. PubMed ID: 25640101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Kearsley-Fleet L; Davies R; De Cock D; Watson KD; Lunt M; Buch MH; Isaacs JD; Hyrich KL;
    Ann Rheum Dis; 2018 Oct; 77(10):1405-1412. PubMed ID: 29980575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs.
    Momohara S; Kawakami K; Iwamoto T; Yano K; Sakuma Y; Hiroshima R; Imamura H; Masuda I; Tokita A; Ikari K
    Mod Rheumatol; 2011 Oct; 21(5):469-75. PubMed ID: 21318306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease-modifying antirheumatic drugs and risk of thyroxine-treated autoimmune thyroid disease in patients with rheumatoid arthritis.
    Waldenlind K; Delcoigne B; Saevarsdottir S; Askling J
    J Intern Med; 2024 Mar; 295(3):313-321. PubMed ID: 37990795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal Trends in Use of Biologic DMARDs for Rheumatoid Arthritis in the United States: A Cohort Study of Publicly and Privately Insured Patients.
    Desai RJ; Solomon DH; Jin Y; Liu J; Kim SC
    J Manag Care Spec Pharm; 2017 Aug; 23(8):809-814. PubMed ID: 28737992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study.
    Dreyer L; Cordtz RL; Hansen IMJ; Kristensen LE; Hetland ML; Mellemkjaer L
    Ann Rheum Dis; 2018 Apr; 77(4):510-514. PubMed ID: 29217620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs.
    Cho SK; Lee J; Han M; Bae SC; Sung YK
    Arthritis Res Ther; 2017 Dec; 19(1):277. PubMed ID: 29246243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of medical complications following total hip or knee arthroplasty in patients with rheumatoid arthritis: A register-based cohort study from Denmark.
    Cordtz R; Odgaard A; Kristensen LE; Overgaard S; Dreyer L
    Semin Arthritis Rheum; 2020 Feb; 50(1):30-35. PubMed ID: 31272806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological Disease-Modifying Antirheumatic Drugs and Osteoporotic Fracture Risk in Patients with Rheumatoid Arthritis: A Danish Cohort Study.
    Abtahi S; Cordtz R; Dreyer L; Driessen JHM; Boonen A; Burden AM
    Am J Med; 2022 Jul; 135(7):879-888.e3. PubMed ID: 35134369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system.
    Rashid N; Lin AT; Aranda G; Lin KJ; Guerrero VN; Nadkarni A; Patel C
    J Med Econ; 2016 Jun; 19(6):568-75. PubMed ID: 26766553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.